Special Issue

Research on Porphyrin and Related Compounds Used in Photodynamic Anticancer and Antimicrobial Therapy

Message from the Guest Editors

This Special Issue aims to highlight recent advances in the design, synthesis, and characterization of porphyrinbased compounds, including porphyrin conjugates, toward new photosensitizers with improved properties for anticancer and antimicrobial photodynamic therapy. Improved characteristic(s) in this area can be one or more of the following: higher production of singlet oxygen/ROS, improved drug delivery and increased bioavailability, selectivity for target cells, increased cellular binding/uptake, specific organelle targeting, overpowering hypoxia, and multifunctional activity (including imaging). In achieving these goals, porphyrins can be used in new formulations, as well as in combination therapies, and it is desirable to show the achieving of a required photodynamic effect with lower drug concentrations and lower light doses. Original research articles are welcome in this Special Issue, which may include in vitro and in vivo studies, as well as reviews.

Guest Editors

Dr. Nela Malatesti

Faculty of Biotechnology and Drug Development, University of Rijeka, Radmile Matejčić 2, HR-51000 Rijeka, Croatia

Dr. Ivana Ratkaj

Faculty of Biotechnology and Drug Development, University of Rijeka, Radmile Matejčić 2, HR-51000 Rijeka, Croatia

Deadline for manuscript submissions

closed (20 September 2025)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/196489

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

